Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over ...

The cell therapy developer, which raised nearly $500 million in 2023 on the promise of its CAR-T work, has floundered since a ...

Today, a brief rundown of news involving CSL and Intellia Therapeutics, as well as updates from Eli Lilly and 23andme that you may have missed. The Food and Drug Administration on Tuesday approved CSL ...

Dive Brief: Novo Nordisk is planning Phase 3 clinical trials for a obesity drug combination called amycretin, adding another emerging weight-loss medicine to the list of prospects it has in advanced ...

An indirect approach Gonzalez said there are alternate routes to regulate LDTs that the FDA could take, where the agency has either brought enforcement action sporadically in the past or suggested it ...

Illumina on Monday said it agreed to acquire SomaLogic and other assets from Standard BioTools for $350 million in cash to expand in the proteomics market. The deal includes additional near-term ...